|
|||||
|
|
Utility of the Huntington's Disease Prognostic Index Score for a Perimanifest Clinical Trial |
|
| Authors: | Douglas R. Langbehn MD PhD Elisabeth M. Fine PhD Andreas Meier MD Steven Hersch MD PhD |
| Affiliation: | 1. Department of Psychiatry, University of Iowa Carver College of Medicine, Psychiatry Research, Iowa City, Iowa, USA;2. Voyager Therapeutics, Inc., Cambridge, Massachusetts, USA;3. Voyager Therapeutics, Inc., Cambridge, Massachusetts, USA Eisai Inc., Woodcliff Lake, New Jersey, USA Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA |
| Abstract: | |
| Keywords: | Huntington's disease prodromal prognostic index clinical trial design |